The covalent binding of proteins with polyethylene glycol (PEG) molecules is a valuable tool to extend the halflife of many biotherapeutics, including factor VIII (FVIII) products to treat patients with haemophilia A. Although PEG has low toxicity, accumulation of large PEG molecules (> 20-30 kDa) with long-term exposure is a potential concern. Thus, it is important to determine whether sufficient excretion processes exist for PEG molecules used in biotherapeutics. BAY 94-9027 is an extended-half-life FVIII product modified through addition of a 60-kDa (branched: dual 30-kDa) PEG molecule. BAY 1025662 is the 60-kDa PEG moiety used for PEGylation of BAY 94-9027. This study investigated the pharmacokinetic (PK) properties, distribution, and excretion of BAY 1025662 in rats in order to predict estimated 60-kDa PEG PK properties in patients. Plasma concentrations in male rats after a single 11-mg/kg intravenous dose of BAY 1025662 (approximating the cumulative PEG-60 exposure in patients during 30 years of BAY 94-9027 treatment) decreased with an initial halflife of 119 h (5 days) in the interval of 114-336 h post administration. Single-dose mass balance studies using radiolabeled BAY 1025662 ([prop-14 C]BAY 1025662) showed that 30.4% of radioactivity was excreted within 1 week and 79.1% by Day 168 (primarily in urine). The terminal half-life of radioactivity elimination was approximately 24 days in blood and plasma and was 31-68 days in the majority of other organs up to Day 168. Elimination was nearly complete at the end of the experiment on Day 168; only~4% of residual radioactivity was present in the animal body. There was no irreversible binding of radioactivity to any tissues and no penetration of the blood-brain barrier. Based on these results, very low steady-state concentrations of 60-kDa PEG were predicted in patients treated with BAY 94-9027, and the validity of these predictions was supported by clinical studies in which almost all 179 patients receiving BAY 94-9027 for prophylaxis had undetectable PEG in plasma for up to > 5 years; those with detectable PEG levels demonstrated concentrations within the predicted range. These combined preclinical and clinical observations suggest that excretion processes are in place for high-molecular-weight PEGs such as the PEG-60 moiety used in BAY 94-9027.
Introduction
Factor VIII (FVIII) has an elimination half-life of 10-14 h, which requires infusions three to four times every week to maintain therapeutic trough blood levels. The frequency and chronicity of FVIII replacement therapy therefore represents a significant burden to patients, their families, and the healthcare system (Bauer, 2015; Mancuso and Santagostino, 2017; Mei et al., 2010) . Technologic advances in the pharmaceutical sciences have resulted in several methods of improving the pharmacokinetic (PK) profile of FVIII, such as modifying it via conjugation with an inert molecule (i.e. polyethylene glycol [PEG] ) (Mancuso and Santagostino, 2017) . PEGylation technology has proven to be a valuable tool for half-life prolongation of proteins by covalent binding of one or more (large) PEG molecules either with general chemical attachment of small (5-10 kDa) PEG molecules or site-directed attachment of large (≤60 kDa) PEG molecules via linker toMolecules of PEG have a simple, repetitive structure and are chemically inert with low toxicity. They are uncharged, water soluble, nonreactive, and without any specific receptors or targets in the body (Schellekens et al., 2013; Webster et al., 2007; Webster et al., 2009 ). Accumulation of large PEG molecules (> 20-30 kDa) remains a possible concern because of their increasingly low clearance with higher molecular size (Yamaoka et al., 1994) . Cellular vacuolation in certain tissues and cell types, which has been observed in nonclinical toxicology studies for~50% of approved PEGylated drugs, is the only effect attributed to PEG thus far (Baumann et al., 2014b; Ivens et al., 2015) . The PK properties of PEGylated proteins are initially driven by the two major parts of the molecule: the protein itself and its conjugated PEG. When the PEG remains after protein catabolism, its biodistribution and PK properties are governed by PEG-related mechanisms, which are outlined in Fig. 1 (Baumann et al., 2014b) .
PEGylated products have a long track record in the clinic with at least 15 PEGylated biopharmaceuticals currently approved in Europe and the United States (Adynovate, 2017; Movantik®, 2016; Stidl et al., 2016; Sylatron™, 2015; Turecek et al., 2016) . Most approved products are used to treat chronic diseases, such as hepatitis, immunodeficiency disorders, renal failure, or autoimmune diseases (e.g., multiple sclerosis, rheumatoid arthritis) (Kolate et al., 2014; Li et al., 2013; Veronese and Pasut, 2005) . Several PEGylated FVIII products are approved or in development for haemophilia A (Mancuso and Santagostino, 2017) ; nonclinical PK, distribution, and excretion data have been published for some of these products (Bjørnsdottir et al., 2016; Stidl et al., 2016) .
BAY 94-9027 is an extended-half-life recombinant FVIII (rFVIII) that is site-specifically conjugated with a single (dual 30-kDa branched) 60-kDa PEG molecule attached via a maleimide linker to a cysteine amino acid in the A3 domain (Coyle et al., 2014; Mei et al., 2010) . Although the 60-kDa PEG linker moiety of BAY 94-9027 (referred to as BAY 1025662 [includes the linker and cysteine residue]) might not have the same PK and distribution behavior as BAY 94-9027, the understanding of its disposition gives important information on the elimination pathway of the liberated PEG generated after the protein component of BAY 94-9027 has been catabolized (Baumann et al., 2014b) . Slight differences in the tissue distribution and excretion of BAY 94-9027 and the PEG-60-only molecule BAY 1025662 may be expected based on experience with a 40-kDa PEGylated molecule and its PEG-only component (Bjørnsdottir et al., 2016) . However, BAY 1025662 was used as a surrogate for a conservative scenario since the PK behavior of the PEG molecule remaining after metabolism of the PEGylated protein ('metabolic PEG') was the target of our study to mimic the slowest possible PK and excretion.
In the current study, Wistar rats were administered a single dose of either radiolabeled or nonlabeled PEG-60-maleimide-cysteine (BAY 1025662), a surrogate for the PEG moiety of BAY 94-9027. Excretion and distribution of BAY 1025662 were then measured in order to determine PEG disposition after catabolism of the BAY 94-9027 protein component.
Materials and methods

Synthesis of BAY 1025662 and [prop-14 C]BAY 1025662
Radiolabeled BAY 1025662 was synthesized in a two-step process to incorporate a [ 14 C] label in the propionic acid moiety in the maleimide linker, which is a common approach for radiolabeled PEGylated proteins (Maxwell et al., 2013; Cao et al., 2014) (Fig. 2) . The PEG amine intermediate SUNBRIGHT GL2-600PA (NOF Corporation, Tokyo, Japan) was coupled with externally synthesized 3-(maleimido) [2,3-14 C] propionic acid N-hydroxysuccinimide ester (Quotient Bioresearch, Cardiff, UK). The conversion was performed in a mixture of acetonitrile and toluene at ambient temperature. The resulting PEGlinker compound was purified by repeated recrystallization from ethyl acetate and reacted with cysteine in physiologic saline to produce the final product in its application form. This final application solution was analyzed by size exclusion and ion-exchange chromatography with offline radioactivity detection to provide evidence for complete synthetic conversion and purity. 
Determination of BAY 1025662 in plasma and urine
The PK properties of BAY 1025662 were evaluated in male Wistar rats after a single 11-mg/kg intravenous (IV) dose (3-4 animals per sampling time [0.0833, 1.5, 7, 24, 48, 72, 96, 144, 192, 240, 288 , and 336 h post administration]). BAY 1025662 levels were determined in plasma samples by HPLC, reversed-phase chromatography and tandem mass spectrometry using the following procedure (K. Kubesch: unpublished data). After protein precipitation using methanol followed by vortexing and subsequent centrifugation, the obtained samples were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) using a non-Good Laboratory Practice validated method. All measurements were performed on a Shimadzu LC-20AD HPLC system (Shimadzu, Japan) hyphenated to an API6500 Triple Quadrupole mass spectrometer (Sciex, Canada). The chromatographic separation was performed on an Onyx Monolithic C18, 100 × 4.6 RP column (Phenomenex, USA). For temperature control, a CTO-20AC column oven (Shimadzu, Japan) was used at a temperature of 60°C. The flow rate was adjusted to 1 mL/min using an injection volume of 50 μL. As the mobile phase, water (H 2 O, mobile phase A) and methanol (MeOH, mobile phase B) were used, both acidified with 0.1% formic acid (v/v). Mobile phase B was increased from 67% to 90% in the time range from 0.0 to 9.5 min (linear gradient). At 9.5-10.8 min, isocratic conditions were run at 100% B. Re-equilibration was performed from 10.8 to 12.0 min at 67% B, resulting in a retention time of 5.4 min. For MS data acquisition, the multiple reaction monitoring mode (MRM) was applied using positive electrospray ionization. To obtain suitable precursor ion candidates, an in-source collision-induced dissociation of BAY 1025662 was performed (Gong et al., 2014) . For data acquisition and analysis, Analyst 1.6.2 was used. As an internal standard, D-PEG-60 K (a deuterated PEG) was used.
Calibration ranged from 1.00 to 200 mg/L in plasma and 0.100 to 10.0 mg/L in urine. Long-term stability of BAY 1025662 was demonstrated in plasma for 11 months (−20°C) and in Tween® 80 modified urine for 33 days (−20°C and −80°C) . To evaluate the stability of the 60-kDa PEG in rat plasma at 37°C for 7 days, two different strategies were applied. First, a sensitive reversed-phase LC-MS/MS method was performed using a specific mass transition (MRM) for quantitative stability assessment comparing the peak area of the 60-kDa PEG at the beginning of the investigation (0 h) and after 7 days (168 h) at 37°C. To further strengthen the assessment, a qualitative size exclusion-liquid chromatography-high resolution mass spectrometry (SEC-LC-HRMS) analysis was performed at the same time points in time-of-flight (TOF) scan mode. Thereby, a change in mass size distribution over time within the mass spectra can additionally be evaluated. For every time point in both strategies, the number of replicates was five using a concentration of 500 mg/L in rat plasma.
All PK parameters following BAY 1025662 infusion were determined using noncompartmental analysis. male Wistar rats as a single IV dose of 11 mg/kg in physiologic saline (0.9%). The group size of 3-4 animals was considered appropriate for the PK studies because previous studies demonstrated low variability of radioactivity concentrations and amounts in plasma, organs, and tissues as well as in excreta. The 11-mg/kg dose approximated the human 30-year dose of PEG 60 kDa resulting from treatment with BAY 94-9027. The animals were sacrificed at selected sample collection times in deep isoflurane anesthesia (approximately 2.5% v/v) by cutting the carotid artery. As much blood as possible was collected. Organs and tissues were not perfused before further sample preparation and radioanalysis. Radioactivity was determined by liquid scintillation counting (LSC; Tri-Carb® 4910TR, PerkinElmer). Fluids (e.g. plasma and urine) were pipetted into the scintillant and directly analyzed. Organ, blood, tissue, and feces samples were combusted using an Oxidizer TRI-CARB 207 (PerkinElmer) and the resulting [
14 C]-labeled CO 2 was captured in liquid scintillant and measured by LSC. Use of the LSC method precluded differentiation between unchanged compound and radioactive metabolites. Therefore, urine samples were investigated up to 7 days after administration via size-exclusion chromatography with offline radioactivity detection ( The radioactivity balance (recovery in excreta and in the residual animal carcasses) was established in a group of 3-4 animals by complete collection of the excreta in special metabolism cages and determination of residues in the animals at 168 h after administration. Additionally, fecal and urinary excretion of radioactivity was investigated for up to 168 and 231 days post administration, respectively. For this purpose, excreta were collected at defined 24-h intervals on Days 14, 28, 56, 84, 26, 168, and 231 (urine only) after administration of the test compound. The arithmetic means values obtained for urinary and fecal radioactivity excretion in the 24-h collection intervals were used for linear interpolation to establish the cumulative urinary and fecal radioactivity excretion between sample collection intervals.
Distribution of total radioactivity in organs and tissues in male Wistar rats was additionally determined by quantitative whole-body autoradiography following IV bolus administration of [prop-14 C]BAY 1025662 (11 mg/kg; one animal per time point [2 and 24 h; 7, 28, 84, and 168 days] ). Animals were euthanized by CO 2 inhalation without any blood withdrawal, deep frozen in dichloromethane/dry ice solution (approximately −70°C), and embedded in a 5% carboxymethylcellulose fixation media. Sagittal whole-body sections were cut (50-μm thick) at −25°C using a cryomicrotome (CM 3600, Leica, Nussloch, Germany) and freeze-dried for ≥24 h. Radioactivity distribution in the whole-body sections was detected with the BAS 5000 phosphor-imaging system (Fuji, Tokyo, Japan). Blood standards spiked with [ 14 C] (10 preassigned concentrations [measured by LSC ranging from 22 to 27,111 Bq/mL] embedded together with each animal) were used as internal calibrators for quantitation of radioactivity in tissues and organs.
Simulation of human plasma, organ, and tissue concentrations of PEG
Rat PK data following administration of a 30-year equivalent PEG dose of BAY 1025662 were used to simulate the PK of 60-kDa PEG in patients being treated with therapeutic doses of BAY 94-9027 via allometric scaling. Based on the nonclinical rat study with [prop-14 C]BAY 1025662, PEG-60 concentrations in plasma, tissues, and organs were simulated for patients after repeated doses of 60 IU/kg BAY 94-9027 every 5 days (corresponding to a maximum weekly dose of 2.8 μg/kg). Allometric scaling factors of 0.8 for clearance and 1 for volumes of distribution were used for upscaling of rat data to estimate the respective human PK parameters. Plasma, organ, and tissue concentration-time curves of PEG 60 kDa were simulated for humans using Phoenix 6.4 (Certara USA, Inc., Princeton, NJ, USA). Furthermore, PEG concentrations were determined in plasma of patients treated with BAY 94-9027 in clinical trials by a validated method using a combination of size-exclusion chromatography and tandem mass spectrometry. The simulated plasma concentration data obtained were compared with the PEG 60-kDa concentrations determined in the plasma of patients treated with three regimens of BAY 94-9027 (30-40 IU/kg 2×/week, 45-60 IU/kg every 5 days, or 60 IU/kg every 7 days) for up to > 5 years (Lalezari et al., 2018; Saxena et al., 2018) .
Results
PK and excretion of BAY 1025662 after single administration including stability assessment at 37°C
A slow but continuous decrease in plasma concentrations of BAY 1025662 over time was observed (Fig. 3) . A half-life of 119 h (5 days) was calculated for the phase between Days 4.75 and 14 after administration (114-336 h post administration). Plasma concentrations decreased to approximately 5% of the maximum concentration (C max ) by the conclusion of the observation period. The plasma clearance was 0.43 mL/h/kg, and the initial volume of distribution was 27 mL/kg, which approximates the plasma volume in rats. The calculated volume of distribution at steady state was 68.4 mL/kg (Table 1) .
Renal excretion of BAY 1025662 accounted for 5.2% of the administered dose within the first 24 h, 13.8% after 7 days, and 17.4% after 336 h (2 weeks). Half-life based on the renal excretion rate was 149 h, which was in a similar range to the elimination half-life (119 h) derived from the plasma concentration-time data (Fig. 3) . The results of the stability assessment of BAY 1025662 using LC-MS/MS and SEC-LC-HRMS in plasma at 37°C for 7 days are shown in Fig. 4 . No significant decrease in peak area (Fig. 4A, B) or change in mass size distribution within the mass spectra (Fig. 4C, D) was observed at 37°C after 168 h. Therefore, the short-term stability of BAY 1025662 can be demonstrated in ex vivo rat plasma for 7 days (37°C), which was quantitatively confirmed by comparing the peak areas of the LC-MS/MS analysis between 0 h and 168 h (degradation < 4.4% over 7 days).
Excretion of [prop-
C]BAY 1025662
After administration of a single IV dose of [prop-14 C]BAY 1025662, 30.4% of the administered radioactivity was excreted within 7 days, predominantly via urine (23.7%) and to a lesser extent in feces (6.3%) and in cage wash (0.4%). Radioactivity excretion steadily declined throughout the rest of the study (Fig. 5A ). Size-exclusion HPLC analysis with offline radioactivity detection suggested that 74% of [prop-14 C] BAY 1025662 radioactivity, corresponding to 17.6% of the total dose, was excreted nearly unchanged in the urine through Day 7 (Fig. 5B) . These results further support the stability of the [ 14 C]-label in the amide moiety of the maleimide linker as no evidence of further PEG metabolism and degradation was observed. Daily radioactivity excretion in urine and feces decreased from 3.6% of the dose at 72 h to 0.03% of the dose at 231 days after administration of [prop-14 C]BAY 1025662. The cumulative excretion of radioactivity via urine and feces was calculated to be 79.1% of the administered radioactive dose through the end of the experiment on Day 168 (64.9% via urine, 13.8% via feces, and 0.4% recovered in the cage wash; Table 2 ). An additional 3.5% of the administered radioactivity was excreted via urine up to 231 days post administration. Radioactivity was slowly and continuously eliminated from organs and tissues, with elimination half-lives of 24 days in both blood and AUC = area under curve; CL = clearance; C max = maximum concentration; RRange = regression range; t 1/2 = half-life; t max = time to C max ; V ss = volume of distribution at steady state. a Used for calculation of half-life.
plasma determined up to 168 days post administration. Radioactivity elimination half-lives were 33 days in liver, 31 days in skin, 39 days in carcass, 54 days in testes, and 68 days in kidney ( Table 2 ). The total recovery of radioactivity (cumulative excretion plus residues in animals) was 82.6% on Day 168 (Table 3) .
Distribution of [prop-
C]BAY 1025662 in Wistar rats
Following IV administration of [prop-14 C]BAY 1025662, radioactivity was slowly but widely distributed from the blood to peripheral organs and tissues (maximum equivalent concentration [Ceq max ] ratio organ-to-blood, < 0.5). The Ceq max was reached 2 h after injection in about half of all organs and tissues investigated; highest concentrations occurred in the blood, lung, and liver (135, 90.6, and 75.5 mg-eq/L, respectively). In the kidney, radioactivity was heterogeneously distributed with a Ceq max ranging from 73.9 mg-eq/L in renal papilla to 39.9 mg-eq/L in renal cortex at 2 h post dose. Lowest Ceq max values of approximately 2 mg-eq/L were observed in the bone, brain, and skeletal muscle (2 h post dose). In other organs and tissues, Ceq max values were reached ≥24 h post dose or later.
Whole-body distribution of radioactivity at Days 7 and 168 after a single 11-mg/kg IV dose is shown in Fig. 6A and B. Blood exposure in terms of area under the curve (AUC) to [prop- 14 C]BAY 1025662 radioactivity was relatively low compared with most tissues and organs. A relatively high exposure was observed in several exocrine and endocrine glands (e.g. adrenals, pineal body, hypophysis, submandibular gland, pancreas, lacrimal glands, and thyroid glands), suggesting a certain affinity of [prop-14 C]BAY 1025662 to the endocrine/exocrine hormonal system in the body. Some radioactivity in lymphatic organs (e.g. spleen, lymph nodes, and thymus) and connective tissue was also seen (exposure comparable to glands). Radioactivity was continuously but slowly eliminated from the body with very similar half-lives as in the excretion study. The elimination half-life in the choroid plexus was approximately 117 days. Exposure in the brain was very low (radioactivity concentration just above the detection limit at Day 7 post dose). The brain C max and AUC of radioactivity were approximately 1.4% of the respective parameters in blood, suggesting no penetration of [prop-14 C]BAY 1025662 across the blood-brain barrier. No residual radioactivity was detected in the brain at later time points. Exposure in the testes was approximately 2-fold higher than in the blood. At Day 168 post dose, 4.2% of the administered radioactive dose remained in the animal body (sum of all organs and tissues excluding the gastrointestinal tract; Fig. 6B ), mainly localized in brown adipose tissue (0.91%), skin (0.75%), testes (0.73%), liver (0.46%), kidneys (0.36%), and spleen (0.28%). In the choroid plexus, 0.006% of the administered radioactive dose was found at Day 168 post dose. In the blood, brain, and skeletal muscle, the radioactivity was below the quantification limit. Thus, elimination of radioactivity was almost complete by Day 168.
Predicted PEG levels in humans after treatment with BAY 94-9027
Based on PK data obtained from the rat tissue distribution study (quantitative whole-body autoradiography) following administration of a 30-year equivalent PEG dose ([prop-14 C]BAY 1025662), the plasma, organ, and tissue concentration-time profiles of PEG 60-kDa were simulated for patients receiving repeated 60-IU/kg BAY 94-9027 doses every 5 days using an allometric approach. Because of the high dose administered in the animal study, these simulations should be regarded as a worst case scenario as demonstrated earlier with another PEGylated FVIII product (Bjørnsdottir et al., 2016) .
According to the simulation, the maximum PEG-60 plasma concentration reached in patients at steady state (C ss ) was predicted to bẽ 0.10 mg/L (C max,ss , 0.10 mg/L; C min,ss , 0.08 mg/L) and thus was consistent with the PEG concentrations observed in the plasma of patients who were treated with BAY 94-9027 in a clinical trial for 0.8-5.4 years (Saxena et al., 2018) . When PEG plasma concentrations were measured in these patients, very few analyzed samples contained detectable PEG-60 concentrations. Detectable results were observed at select time points that were slightly above the lower limit of quantitation (0.10 mg/L); only five out of 179 patients analyzed had detectable levels at single time points, and three of the five patients had undetectable PEG levels in ≥2 follow-up measurements (Saxena et al., 2018) . This confirms the validity of the applied simulation approach and demonstrates that the PEG-60 PK in patients treated with BAY 94-9027 can be reasonably predicted based on PK data from rats treated with the surrogate BAY 1025662.
The corresponding simulated maximum steady-state concentrations of PEG-60 in patients were predicted to be~0.12 mg/L in liver, 0.17 mg/L in kidney, and 0.6 mg/L in the choroid plexus after administration of therapeutic BAY 94-9027 doses (60 IU/kg [~2 μg/kg] every 5 days) for~4 years.
Discussion
The study reported here evaluated the PK properties of BAY 1025662 in experiments in male rats using both a nonlabeled and a [ 14 C]-labeled compound with 94% radiochemical purity. BAY 1025662 was eliminated from plasma with a half-life of 5 days during the interval of 114-336 h post administration. The half-life of BAY 1025662 calculated using the renal excretion rate was similar to the elimination half-life derived from the plasma concentration-time data in this phase, indicating a close relation between renal excretion and half-life in circulation. Nonspecific uptake into cells and subsequent release back into plasma may lead to a longer elimination half-life for large PEG molecules (Baumann et al., 2014b) . The proposed mechanisms of cellular uptake and redistribution of PEG (Fig. 1) indicate that PEG or PEGylated proteins can undergo pinocytosis and internalization by endosomes and lysosomes, and PEG gradually accumulates in the lysosomes because of the lack of mammalian etherases (Stidl et al., 2016; Webster et al., 2007) . Redistribution of PEG from lysosomes into blood may occur either through exocytosis or cell turnover (Baumann et al., 2014b) . The rate of cellular uptake and excretion is determined by the size of the PEG, the characteristics of the PEGylated protein, existing nonspecific uptake or receptor-mediated cellular uptake, the PEG dose and dosing frequency, and the turnover kinetics of the cells involved in PEG uptake (Baumann et al., 2014b; Ivens et al., 2013) .
A single-dose mass balance study tracing radiolabeled BAY 1025662 for 168 days post administration showed that nearly one-third of administered radioactivity was excreted by Day 7, and 79.1% was excreted by Day 168 (primarily in urine). An additional 3.5% of the administered radioactivity was excreted via urine by Day 231. The RRange = regression range; t 1/2 = half-life.
A. Baumann et al. European Journal of Pharmaceutical Sciences 130 (2019) 11-20 elimination half-life of radioactivity was approximately 24 days in blood, and longer in most organs and tissues. Elimination was nearly complete by Day 168 with only~4% of radioactivity detected in the animal body. Maximum radioactivity concentrations (Ceq max ) were higher in blood than in all other organs and tissues investigated, although radioactive exposure in terms of AUC was highest particularly in well-perfused organs and tissues. Compared with blood, radioactivity AUC was 2-to 5-fold higher in organs and tissues including the choroid plexus, endocrine and exocrine glands, spleen, excretory organs, testes, and bone marrow. This indicates slow distribution from the blood to organs and tissues. Brain C max and AUC of radioactivity were 1.4% of the respective parameters in blood, and thus expected to be the result of residual blood in the brain blood vessels rather than penetration into the brain tissue. This indicates that [prop-14 C]BAY 1025662 does not penetrate the blood-brain barrier.
In previous toxicology studies, no cellular vacuolation or adverse events were observed in rats and rabbits administered repeated high doses of BAY 94-9027 (38-fold higher than the clinical 60-IU/kg dose) or BAY 1025662 (up to 5500-fold higher than the PEG content of 60 IU/ kg BAY 94-9027) (Ivens et al., 2013) . Thus, the high PEG-60 exposure and long PEG-60 elimination half-life observed in the current study in rat choroid plexus after [prop- 14 C]BAY 1025662 administration were unlikely to be associated with vacuolation. This is further supported by studies in rats with the PEG-40-containing coagulation factors N8-GP (Novo Nordisk, Bagsvaerd, Denmark) and N9-GP (Refixia®, Novo Nordisk), in which similar distribution patterns of PEG-40, slow elimination, long half-lives, and lack of vacuolation in the choroid plexus were observed after 26 or 52 weeks of N8-GP treatment at relevant doses (Rasmussen et al., 2016; Rasmussen et al., 2017) or after 52 weeks of N9-GP treatment at much higher doses (Refixia®. Summary of Product Characteristics, 2018). The current PK results in rats administered 11 mg/kg BAY1025662 and [prop-
14 C]BAY 1025662 confirm previous reports in the literature regarding PEG distribution and elimination (Bjørnsdottir et al., 2016; Longley et al., 2013; Stidl et al., 2016; Yamaoka et al., 1994) . The urinary excretion of PEG-60 ([prop-14 C]BAY 1025662) reported here (68% of dose excreted 231 days after administration) is consistent with current knowledge; for example, a preclinical rat study investigating PK of N8-GP (Bjørnsdottir et al., 2016) found that 75% and 62% of [ continued so that no retention of PEG-60 is expected. The European Medicines Agency suggests that before clinical studies lasting ≥4 weeks are conducted, PEGylated products should be assessed in nonclinical studies for ependymal cell vacuolation, presence of active transport mechanisms for PEG across the blood-brain barrier, and whole-body biodistribution (European Medicines Agency, 2012). Excretion and distribution studies with other PEGylated rFVIII products (BAX 855 [Adynovate®, Shire, Westlake Village, CA, USA; two 10-kDa branched PEG chains totaling 20 kDa]) (Stidl et al., 2016) and N8-GP (Bjørnsdottir et al., 2016) and their corresponding PEG moieties showed that 20-and 40-kDa PEG moieties were widely distributed. Preclinical studies of radiolabeled BAX 855 showed that radioactivity was extensively distributed, particularly in plasma, blood, mesenteric lymph nodes, spleen, liver, adrenal glands, and kidneys. Marginal radioactivity was detected in the central nervous system (CNS), even after radiolabeled BAX 855 doses 25 to 50 times the maximum clinical dose. Excretion was complete within 6 weeks (Stidl et al., 2016) . With regard to N8-GP, single-dose studies in rats exposed to both [
H]N8-GP and [
3 H]PEG demonstrated that radioactivity was widely distributed (the lowest radioactivity levels were in the CNS) and slowly excreted (primarily in the urine), with half of the radioactivity eliminated after 1 week (Bjørnsdottir et al., 2016) . The presence of relatively high levels of radioactivity in lymphatic system tissues, such as lymph, mandibular lymph nodes, and spleen, following administration of 40-kDa (Bjørnsdottir et al., 2016) as well as 60-kDa PEG (observed in the present study) suggest a role for lymphatic uptake in PEG disposition.
In preclinical toxicology studies, histologic evidence of cellular vacuolation in macrophages and histiocytes in renal tubular and ependymal cells of the choroid plexus following repeated PEG exposure has been observed in association with some PEGylated therapeutics (Forest et al., 2017; Ivens et al., 2015; Rudmann et al., 2013) . PEG vacuolation of macrophages in the ependymal cells of the choroid plexus of the brain and other organs of cynomolgus monkeys has been reported with long-term (26 and 52 weeks) studies of certolizumab pegol (Cimzia®, UCB, Inc., Smyrna, GA, USA; a 40-kDa PEG moiety) in doses of 50 and 100 mg/kg, which were higher than the no-effect-level dose of 10 mg/ kg (Horton et al., 2012) . However, no adverse effects on choroid plexus integrity or function or on neurobehavioral and learning abilities were associated with vacuolation. Previous results from short-term preclinical studies of BAY 94-9027 have not demonstrated systemic toxicity regarding either FVIII-related or PEG-related adverse events, and cellular vacuolation has not been observed (Ivens et al., 2013) . Very low doses of PEG (2.8 μg/kg/week) are given with the highest dose prophylactic regimen of BAY 94-9027 in humans (60 IU/kg BAY 94-9027 every 5 days). These doses of PEG are > 750-fold lower than the maximum acceptable administrable daily dose of PEG in humans according to the Committee for Medicinal Products for Human Use Safety Working Party's paper for the pediatric population (European Medicines Agency, 2012) . Moreover, the highest weekly dose of BAY 94-9027 is below clinical doses used for PEGylated products in other therapeutic areas and three orders of magnitude below doses of PEG shown to induce macrophage vacuolation in animal tissues (Baumann et al., 2014a; Ivens et al., 2013) .
The profile of the observed elimination pattern of BAY 1025662 suggests that there are two potential clearance processes for large PEGs (> 20-30 kDa) as indicated by a faster initial excretion phase over the first 1 to 2 weeks followed by a slower nonspecific uptake phase into cells by pinocytosis leading to a longer elimination half-life. Both the present tissue distribution study using a 60-kDa PEG molecule and earlier reports with 40-kDa PEG molecules (Bjørnsdottir et al., 2016) also suggest that PEG can be recycled from inside the cells back to the plasma, possibly by exocytosis, to then undergo further excretion. Nevertheless, total clearance decreases with increasing PEG size. Based on data modeled using observed terminal half-lives (15-49 days) measured in rat tissues, the 40-kDa PEG moiety was estimated to reach steady-state levels in human plasma after 6 months and in tissues after 1 to 2 years Sternebring et al., 2017) . The steady-state levels of the 60-kDa PEG after BAY 94-9027 administration in humans are estimated to be reached in plasma after about 1 year and in tissues after 2 to 4 years based on a worst case scenario approach due to the high dose of BAY 1025662 used in the animal study. PK drug accumulation occurs under multiple-dosing regimens as each dose adds to the residual amount of drug in the body and depends on clearance (half-life) and dosing interval. This does not mean that the drug stays forever in the body, if a steady state is reached and excretion processes are demonstrated as seen for large PEGs (including 60 kDa) and PEGylated proteins. Accumulation is a common observation in PK studies of many drugs and does not on its own indicate adverse effects or toxicity (Rowland and Tozer, 2011) . The time to reach steady state is dependent on the PEG size (which determines clearance and thus elimination half-life) and is an important piece of information for planning preclinical animal studies. Steadystate concentrations are driven by the individual PEG load of the PEGylated protein and the resulting administered PEG dose. The important consideration is to evaluate if the drug level at steady state is associated with any possible adverse effects. The individual PEG dose of different PEGylated proteins in nonclinical and clinical studies is A. Baumann et al. European Journal of Pharmaceutical Sciences 130 (2019) 11-20 described based on published data (Fig. 7) . Because of the relatively long elimination half-lives in relation to dosing intervals, PEG is expected to accumulate in organs and tissues after repeated BAY 94-9027 administration until a steady state is reached. Once at steady state, the equivalent of one dose is eliminated during each dosing interval so that drug concentrations remain constant across subsequent dosing intervals in blood, plasma, organs, and tissues. Using an allometric scaling approach, the PEG-60 steady-state exposures resulting from treatment of patients with therapeutic doses of BAY 94-9027 were simulated based on nonclinical data. Simulated concentration-time profiles of PEG-60 and PEG-40 (used in N9-GP) were compared for plasma, kidneys, liver, and choroid plexus after repeated administration of 60 IU/kg BAY 94-9027 every 5 days (~2 μg/ kg PEG-60 per dose or maximally 2.8 μg/kg PEG-60 per week) and 40 IU/kg N9-GP once weekly (~230 μg/kg PEG-40 per week). Patients' steady-state concentrations of PEG-40 (C max,ss ) were estimated to be 119-, 17-, and 11-fold higher in the liver, kidney, and choroid plexus, respectively, after treatment with N9-GP compared with PEG-60 concentrations after treatment BAY 94-9027. No adverse effects of PEG-40 or PEG-60 exposure were reported after chronic treatment of patients with N9-GP (Refixia, 2017) or BAY 94-9027 (up to > 5 years of treatment) (Saxena et al., 2018) .
Among the PEGylated biopharmaceuticals associated with tissue vacuolation, toxicology studies demonstrated that vacuolation occurrence, incidence, and severity increased with dose, dosing frequency, and dosing duration (Ivens et al., 2015; Ivens et al., 2013) . Vacuolation was not associated with any pathologic effects (tissue degeneration, necrosis, or cellular distortion) or changes in study endpoints related to hematology, clinical chemistry, urinalysis, or organ weight (Ivens et al., 2015; Lenz et al., 2018) . Although no changes in physiology or function have been reported, it remains unknown whether vacuoles caused by more prolonged exposure to higher molecular weight PEG may have functional consequences (Ivens et al., 2015) .
These results are consistent with those of another study (Rasmussen et al., 2017) , in which no vacuolation was detected by light microscopy in immunodeficient rats after chronic administration of low doses of PEGylated FVIII. This was likely because of the low doses used, reflecting the low dose ranges needed for therapeutic efficacy of FVIII products, including BAY 94-9027. In recent investigations in rats, it was proposed that PEG-40 blood concentrations > 100 μg/mL may cause tissue vacuolation (Jacobsen and Bjørnsdottir, 2017) . This is several orders of magnitude higher than concentrations observed either in preclinical studies (including those using very high doses of BAY 94-9027 or PEG-60 only) or in clinical studies, in which plasma concentrations were < 0.1 μg/mL for almost all patients using therapeutic doses of BAY 94-9027. This also confirmed the validity of the applied simulation approach and demonstrated that the PEG-60 PK in humans after treatment with BAY 94-9027 can reasonably be predicated based on PK data obtained in rat studies after administration of the surrogate BAY 1025662. Additionally, an important consideration is that if steady-state PEG concentrations in tissues and organs are below the threshold concentration where vacuolation is associated with morphologic changes, PEG is not expected to affect organ function (Ivens et al., 2015) .
Conclusions
Following single-dose administration of the 60-kDa PEG component of BAY 94-9027 ([prop-14 C]BAY 1025662) to male rats, which approximated the PEG dose that patients would receive with 30 years of BAY 94-9027 treatment, several conclusions can be drawn. Primarily, results demonstrated that excretion processes are in place for higher molecular weight PEGs, such as the PEG-60 moiety used in BAY 94-9027. Large PEG molecules (≥20 kDa) are continuously but slowly eliminated, resulting in long elimination half-lives in organs and tissues; thus, PEG accumulates with repeated dosing until a steady state is reached. Once a steady state is reached, the PEG concentration in plasma, organs, and tissues remains constant with no further accumulation.
Moreover, plasma steady-state concentrations of PEG-60 in patients receiving therapeutic doses of BAY 94-9027 were similar to predictions based on nonclinical PK studies, suggesting that the modeling of organ and tissue concentrations can accurately predict results in humans. No safety concerns were reported in patients after chronic treatment with BAY 94-9027.
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